Back to Results

Drugs Made In America Acquisition Unit (DMIIU)

Featured in Bullish Trend Stocks

Drugs Made In America Acquisition Unit (DMII.U) is a NASDAQ-listed hybrid security classified as a debt/equity composite unit. The unit is associated with Drugs Made In America Acquisition II Corp., a company that currently has no significant operating business. The issuer was formed in 2024 and is based in Fort Lauderdale, Florida. Its stated objective is to complete a business combination through a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or a similar transaction with one or more businesses.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield P/E Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-DMII.U
$6.93
-32.4% Downside
Overvalued
Not available
Not available
Fair
0.0%
49.8x
647.8 M
648.1 M
0.1%
78.9%
0.7
-9.8%
Valuation • Fair Value

Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) Fair Value by Valuation Model

Review the available estimates for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U), including Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$6.93

Estimated downside of 32.4% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Ben Graham Formula Value

$2.27

Classic Ben Graham valuation formula reference.

Comps Fair Value

$6.93

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 4 available valuation references for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Altman Z-Score

0.7

Lower score that deserves closer risk review.

FCF / Net Income

-9.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U). No upcoming dividend amount or event date is currently available.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) Stock FAQ

Data-supported answers about Drugs Made In America Acquisition Unit (NASDAQ-DMII.U), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$6.93
Estimated downside 32.4%
Valuation Rating
Overvalued
Estimated downside of 32.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) is $6.93. This implies an estimated downside of 32.4% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 32.4% versus the current market price.

The current financial health read for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U).

The current P/E ratio listed for Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) is 49.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Drugs Made In America Acquisition Unit is 647.8 M.

The current enterprise value listed for Drugs Made In America Acquisition Unit is 648.1 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Drugs Made In America Acquisition Unit is NASDAQ-DMII.U, and the stock is listed on NASDAQ.

Drugs Made In America Acquisition Unit (NASDAQ-DMII.U) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Drugs Made In America Acquisition Unit is 0.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Drugs Made In America Acquisition Unit is 78.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Capital Markets Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

MS NYSE Morgan Stanley Fair Value Fair Market Cap 318.2 B
MS_PA NYSE Morgan Stanley Pa ADR Fair Value Undervalued Market Cap 318.2 B
MS_PE NYSE Morgan Stanley Pe ADR Fair Value Undervalued Market Cap 318.2 B
MS_PF NYSE Morgan Stanley Pf ADR Fair Value Undervalued Market Cap 318.2 B
MS_PI NYSE Morgan Stanley Pi ADR Fair Value Undervalued Market Cap 318.2 B
GS NYSE Goldman Sachs Group Inc Fair Value Fair Market Cap 285.2 B
SCHW NYSE Charles Schwab Corp Fair Value Undervalued Market Cap 182 B
BLK NYSE BlackRock Inc Fair Value Fair Market Cap 173.7 B
BX NYSE Blackstone Inc Fair Value Undervalued Market Cap 155.6 B
UBS NYSE UBS Group AG Fair Value Fair Market Cap 154.8 B
IBKR NASDAQ Interactive Brokers Group Inc Fair Value Fair Market Cap 151.4 B
SPGI NYSE S&P Global Inc Fair Value Fair Market Cap 119.5 B
HOOD NASDAQ Robinhood Markets Inc Fair Value Overvalued Market Cap 107.7 B
BNY NYSE Bank of New York Mellon Corp Fair Value Fair Market Cap 104.3 B
CME NASDAQ CME Group Inc Fair Value Fair Market Cap 99.24 B
KKR NYSE KKR & Co LP Fair Value Fair Market Cap 88.695 B
ICE NYSE Intercontinental Exchange Inc Fair Value Undervalued Market Cap 87.28 B
BN NYSE Brookfield Corp Fair Value Fair Market Cap 83.795 B
MCO NYSE Moodys Corporation Fair Value Fair Market Cap 81.151 B
BAM NYSE Brookfield Asset Management Inc Fair Value Fair Market Cap 73.598 B